Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novo Nordisk shares were quoted at $44.535 and stayed flat on Thursday morning. China cleared Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), described as the first approved GLP-1 receptor agonist in China.
Novo Nordisk said Wegovy has been approved in China for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), described as the first GLP-1 RA class of drugs for that indication in the country.
Novo Nordisk said Wegovy has been approved in China as the first and only GLP-1 RA for the treatment of MASH.
Novo Nordisk said Wegovy was approved in China as the first and only GLP-1 receptor agonist for the treatment of MASH.